Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN18173987
ISRCTN18173987
Completed
Not Applicable

A trial to compare radiotherapy alone with radiotherapy followed by chemotherapy in the treatment of non-Hodgkin's lymphoma

Cancer Research UK (CRUK) (UK)0 sites0 target enrollmentJuly 1, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsymphoma (non-Hodgkin's)CancerLymphoma (non-Hodgkin's)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ymphoma (non-Hodgkin's)
Sponsor
Cancer Research UK (CRUK) (UK)
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2001
End Date
November 3, 1992
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Cancer Research UK (CRUK) (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Aged 15\-65 years
  • •2\. Proven non\-Hodgkin's disease with good pathology involving nodes, Waldeyer's ring is also included provided that nodes are also involved
  • •3\. Stage I or II

Exclusion Criteria

  • •Patients with abdominal nodes only are excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A randomised trial of radiotherapy alone versus three cycles of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy plus radiotherapy versus six cycles of CHOP chemotherapy plus radiotherapy for early stage aggressive non-Hodgkin's lymphomaon-Hodgkin's lymphomaCancerNon-Hodgkin's lymphoma
ISRCTN55593137Cancer Research UK (CRUK) (UK)
Completed
Not Applicable
Comparison of radical radiotherapy with or without chemotherapy for poor prognosis carcinoma of cervixCervix cancerCancerCervix
ISRCTN38929731Cancer Research UK (CRUK) (UK)
Completed
Not Applicable
Phase I trial evaluating combined radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladderbladder cancerBladder carcinoma10004994
NL-OMON34833Antoni van Leeuwenhoek Ziekenhuis31
Recruiting
Phase 2
A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancerinoperable or recurrent PD-L1 positive triple negative breast cancer
JPRN-jRCTs021210010Suzuki Yoshiyuki20
Active, not recruiting
Phase 1
Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. - Codeleted
EUCTR2008-007295-14-ATEORTC488